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Abstract: Multidrug-resistant bacteria are a global health problem. One of the last-resort antibiotics
against Gram-negative bacteria is the cyclic lipopeptide colistin, displaying a flexible linker with
a fatty acid moiety. The aim of the present project was to investigate the effect on antimicrobial
activity of introducing fatty acid moieties of different lengths and in different positions in a cyclic
peptide, S3(B), containing a flexible linker. The lipidated analogues of S3(B) were synthesized
by 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide synthesis. Following assembly of the
linear peptide by Fmoc solid-phase peptide synthesis, on-resin head-to-tail cyclization and fatty
acid acylation were performed. The antimicrobial activity was determined against the ESKAPE
pathogens, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Escherichia coli. Furthermore, hemolytic activity was determined against human erythrocytes.
A total of 18 cyclic lipopeptides were synthesized and characterized. It was found that introduction
of fatty acids in positions next to the flexible linker was more strongly linked to antimicrobial activity.
The fatty acid length altered the overall hydrophobicity, which was the driving force for both high
antimicrobial and hemolytic activity. Peptides became highly hemolytic when carbon-chain length
exceeded 10 (i.e., C10), overlapping with the optimum for antimicrobial activity (i.e., C8–C12). The most
promising candidate (C8)5 showed antimicrobial activity corresponding to that of S3(B), but with an
improved hemolytic profile. Finally, (C8)5 was further investigated in a time-kill experiment.
Keywords: cyclic lipopeptides; colistin; antimicrobial peptides; fatty acid; hydrophobicity
1. Introduction
The inappropriate use of antibiotics has resulted in a global health crisis wherein multidrug-resistant
bacteria often are encountered in healthcare-associated infections [1]. Especially worrying are the
ESKAPE pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter spp. [2]. Currently, the treatment options are
very limited, and the annual death toll caused by antimicrobial resistance is predicted to rise
to 10 million by 2050 [3]. Therefore, the development of novel antimicrobial agents is of great
importance. A recent survey of the preclinical antibacterial pipeline, ending May 2019, identified 407
preclinical trials, including direct-acting agents, antibodies and vaccines, phages and phage-related
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products, microbiota-modulating therapies, antivirulence approaches, antimicrobial potentiators,
repurposed drugs, and immunomodulatory molecules [4]. Furthermore, siderophore-antibiotic
conjugates such as cefiderocol constitute an interesting new class of antibacterial agents [5].
Antimicrobial peptides (AMPs) were discovered in the 1980s, and they have since received attention
as potential antibiotic candidates [6]. AMPs are a part of the innate immune system of multicellular
organisms, and show high cell selectivity and broad-spectrum activity against several bacterial
species [7,8]. Furthermore, they also display numerous other properties, including wound-healing,
anti-cancer activity, and cell recruitment [9]. Typically, AMPs are less than 40 residues in length, cationic,
and contain approximately 50% hydrophobic residues. AMPs mainly act by disrupting the bacterial
membrane [10], although intracellular targets have been reported [11]. In addition, Velkov et al. looked
at the secondary mode of action cationic peptides against respiratory enzymes such as NDH-2 in the
bacterial membrane [12].
However, the use of AMPs as therapeutics has been hampered by their susceptibility to proteases
and low bioavailability [13]. Introduction of nonstandard amino acids into the AMP sequence may
circumvent these shortcomings. The resulting peptidomimetics often retain the antimicrobial activity of
the parent peptides and are stable to proteolytic breakdown [14]. An alternative strategy for increasing
their stability is to cyclize the AMPs [15].
The cyclic lipopeptide antibiotics colistin (polymyxin E) [16] and daptomycin [17] are considered
to be two of the last-resort drugs available for the treatment of multidrug-resistant Gram-negative
and Gram-positive bacteria, respectively. These lipopeptides consist of a cyclic peptide displaying a
flexible exocyclic linker with a fatty acid tail.
The cyclic antimicrobial peptide S3(B), containing a flexible linker but no lipid tail, was recently
reported by our group [18]. This peptide is structurally similar to the nonapeptides developed by Vaara
et al. from polymyxins [19]. However, S3(B) had activity against S. aureus and P. aeruginosa, but no
activity against other Gram-negative species tested. It is known that the fatty acid chain, e.g., in colistin,
is essential for conferring high antimicrobial activity [20]. Thus, the aim of the present work was to
investigate the effect of introducing fatty acid moieties of different lengths and at different positions in
the structure of S3(B), thereby designing lipopeptide analogues of S3(B).
These lipidated analogues of S3(B) were synthesized by Fmoc-based solid-phase peptide synthesis
(SPPS), as depicted in Scheme 1. After reaching the desired sequence, on-resin head-to-tail cyclization
and fatty acid acylation were performed. Peptides were purified by preparative HPLC, and further
characterized by analytical RP-HPLC and MALDI-TOF MS. A total of 18 cyclic lipopeptides (Figure 1)
were synthesized and investigated. It was found that attachment of fatty acids in positions next to the
flexible linker was particularly strongly linked to high antimicrobial activity.
The antimicrobial activity was determined against the ESKAPE pathogens, while hemolytic
activity was determined against human erythrocytes. The most promising candidate, (C8)5, based on
its low hemolytic activity, was further investigated in a time-kill experiment.
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Figure 1. Structure of fatty acid S3(B) analogues studied in this paper.
2. Results and Discussion
2.1. Optimization of Synthesis
A total of 18 analogues of S3(B), acylated with fatty acids, were synthesized by Fmoc-based SPPS
See Figure S1 and Tables S1–S3. The length and positioning (i.e., at Residues 1, 2, 4, 5, 7, and 8) of
the fatty acid were varied to investigate how these parameters affect both the antimicrobial activity
Int. J. Mol. Sci. 2020, 21, 5829 5 of 18
and hemolytic activity of the peptides. The fatty acid was either introduced directly onto an existing
cationic residue displaying a temporarily protected amine functionality (i.e., Dab1, Dab4, or Dab8) or
by replacing an already hydrophobic residue (i.e., Nal2, Bip5, or Nal7) with a Dab residue carrying the
fatty acid moiety (also introduced via a two-step deprotection-acylation protocol). The peptides were
named according to the position and length of the fatty acid, e.g., (C10)1 indicates that Dab1 is carrying
a C10 fatty acid in the cyclic structure (Table 1).
Initially, our intention was to synthesize all six main peptide analogues displaying a C10 fatty
acid (i.e., 1, 2, 5, 9, 15, and 18) as well as those displaying three longer fatty acids: C12, C14, and C16.
However, after synthesis of the C10 analogues it was realized that solubility of the crude products was
a problematic aspect. In particular, the highly hydrophobic peptides (C10)1, (C10)4, and (C10)8, in which
a cationic side chain was replaced with a hydrophobic one, were found to possess low solubility.
Consequently, these peptides were only synthesized with a C10 fatty acid attached. However, for the
subseries of peptides, in which an aromatic residue was substituted by a Dab residue carrying a
fatty acid, the analogues with elongated fatty acids, i.e., (C12)2/(C14)2, (C12)5/(C14)5, and (C12)7/(C14)7,
were synthesized. These peptides also proved difficult to dissolve.
After peptide cyclization, we often observed a side product with a molecular weight equal to the
cyclic peptide plus 139 Da. Judging from the HPLC retention times, this corresponded to a compound
more hydrophobic than the respective target peptides. Possible explanations could be: (i) addition
of a residual product from the ivDde group, as the ring in this structure corresponded to 139 Da;
(ii) addition of Dmb to the peptide during TFA cleavage, or (iii) a side reaction with the coupling
reagent DMTMM. We excluded that the side product was related to ivDde, since the side product was
also observed in the less hydrophobic and unacylated peptide S3(B), in which the ivDde group had not
been present during synthesis. This was confirmed by the observation that the peak only was present
after cyclization, and not in the linear peptides.
In the literature, it is described that removal of the Dmb group via mild acetic conditions can
lead to peptides with unacceptably low purity. To optimize, addition of scavengers to the cleavage
cocktail was shown to improve trapping of reactive carbocations that give rise to undesired side
reactions [21]. Therefore, it was reasonable to assume that the common impurity was related to
this step in the synthesis. However, a side product involving addition of Dmb was ruled out since
the molecular weight of the Dmb group is 151 Dalton and cyclization together with Dmb requires
133 Dalton. Instead, the side product was most likely related to the 4,6-dimethoxy-1,3,5-triazine part of
the coupling reagent DMTMM, which corresponds to a mass of 139 Da. To alleviate this problem we
used another cleavage cocktail that consisted of TFA/H2O/DTT/TIS (88:5:5:2) [22]. Dithiothreitol (DTT)
is a nucleophilic scavenger originally used for reduction of disulfide bonds [23]. When including DTT
in the cleavage cocktail, there was an improvement for all synthesized C4–C8 peptides in terms of
solubility and purity. The crude peptides were now easily soluble even in water prior to purification.
For the present peptides, introduction of fatty acids in different positions changed two important
parameters: the positive net charge of the molecule and its hydrophobicity. Overall, peptides (C10)1,
(C10)4, and (C10)8 were highly hydrophobic because C10 was attached directly onto an already existing
Dab residue. Therefore, these peptides were composed of three hydrophobic aromatic residues
and one C10 chain, and had a positive net charge of +3 at physiological conditions. In contrast,
the peptides (Cn)2, (Cn)5, and (Cn)8 had the fatty acid attached to a Dab residue instead of Nal or
Bip. Thus, these subseries of peptides contained only two hydrophobic aromatic residues besides the
fatty acid moiety, thereby being less hydrophobic than the other main subseries where the fatty acids
were introduced as an additional hydrophobic moiety. Additionally, for these peptides, the positive
net charge was +4 similar to that of S3(B), displaying three hydrophobic aromatic residues and no
fatty acid. Peptide names, sequences, hydrophobicity, and data obtained from the antimicrobial and
hemolytic experiments are listed in Table 1. Since none of the analogues showed activity against K.
pneumoniae (MIC 64 µg/mL), this bacterium is not discussed further.
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Table 1. Minimum inhibitory concentration values (µg/mL).
Nr ID Peptide EC a SA b AB c PA d KP e %H f %B g
S3(B) c(Dab-Nal-Arg-Dab-Bip-O2Oc-Nal-Dab-Asn) 16 8 16 8 >64 77 71
1 (C10)1 c(Dab(C10)-Nal-Arg-Dab-Bip-O2Oc-Nal-Dab-Asn) >64 8 8 64 64 100 84
2 (C10)2 c(Dab-Dab(C10)-Arg-Dab-Bip-O2Oc-Nal-Dab-Asn) 32 4 16 8 >64 100 76
3 (C12)2 c(Dab-Dab(C12)-Arg-Dab-Bip-O2Oc-Nal-Dab-Asn) 64 16 64 32 >64 100 79
4 (C14)2 c(Dab-Dab(C14)-Arg-Dab-Bip-O2Oc-Nal-Dab-Asn) >64 64 >64 >64 >64 100 84
5 (C10)4 c(Dab-Nal-Arg-Dab(C10)-Bip-O2Oc-Nal-Dab-Asn) 64 8 16 >64 64 100 85
6 (C4)5 c(Dab-Nal-Arg-Dab-Dab(C4)-O2Oc-Nal-Dab-Asn) 64 >64 >64 32 >64 5 62
7 (C6)5 c(Dab-Nal-Arg-Dab-Dab(C6)-O2Oc-Nal-Dab-Asn) 32 32 64 16 >64 13 65
8 (C8)5 c(Dab-Nal-Arg-Dab-Dab(C8)-O2Oc-Nal-Dab-Asn) 16 8 16 8 >64 42 69
9 (C10)5 c(Dab-Nal-Arg-Dab-Dab(C10)-O2Oc-Nal-Dab-Asn) 16 4 8 4 >64 100 74
10 (C12)5 c(Dab-Nal-Arg-Dab-Dab(C12)-O2Oc-Nal-Dab-Asn) 32 4 16 8 >64 100 78
11 (C14)5 c(Dab-Nal-Arg-Dab-Dab(C14)-O2Oc-Nal-Dab-Asn) 32 16 >64 64 >64 100 83
12 (C4)7 c(Dab-Nal-Arg-Dab-Bip-O2Oc-Dab(C4)-Dab-Asn) 64 64 64 64 >64 4 64
13 (C6)7 c(Dab-Nal-Arg-Dab-Bip-O2Oc-Dab(C6)-Dab-Asn) 32 16 64 16 >64 8 69
14 (C8)7 c(Dab-Nal-Arg-Dab-Bip-O2Oc-Dab(C8)-Dab-Asn) 16 8 16 8 >64 56 71
15 (C10)7 c(Dab-Nal-Arg-Dab-Bip-O2Oc-Dab(C10)-Dab-Asn) 16 4 8 8 >64 100 74
16 (C12)7 c(Dab-Nal-Arg-Dab-Bip-O2Oc-Dab(C12)-Dab-Asn) 16 4 16 8 >64 96 79
17 (C14)7 c(Dab-Nal-Arg-Dab-Bip-O2Oc-Dab(C14)-Dab-Asn) 64 16 >64 64 >64 98 84
18 (C10)8 c(Dab-Nal-Arg-Dab-Bip-O2Oc-Nal-Dab(C10)-Asn) 64 4 16 >64 >64 100 84
19 Ref Colistin 0.25 N/A 0.25 0.25 0.5 N/A N/A
20 Ref Vancomycin N/A 0.5 N/A N/A N/A N/A N/A
a E. coli ATCC 29,522 (EC), b S. aureus ATCC 29,213 (SA)), c A. baumannii ATCC 19,606 (AB), d P. aeruginosa ATCC 27,853 (PA), e K. pneumoniae (KP), f percent hemolytic activity against red
blood cells at 150 µM. g %B at peak of elution in analytical HPLC. N/A: not applicable.
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2.1.1. Composition of the Growth Media in MIC Determinations
In the original report on S3(B), MIC experiments were carried out by using non-cation-adjusted
MHB-I media. To this, bovine serum albumin (BSA) and acetic acid were added. The rationale for
choosing a medium without cations is that cation-adjusted media (MHB-II) in some cases causes
substantial inhibition of the activity of cationic peptides. Furthermore, some peptides are at risk of
precipitation when diluted into MHB medium, which can be avoided via the addition of BSA and
acetic acid [24]. However, the use of MHB-II is favorable to imitate the in vivo conditions as much as
possible. Both media were tested with and without the addition of BSA and acetic acid by trial and error.
The use of pure MHB-II was compatible with S3(B) and its fatty acid analogues, and therefore was
chosen for the MIC determinations. Noticeably, MHB-I with BSA and acetic acid led to precipitation of
lipopeptides in the present work.
2.1.2. Fatty Acid Positioning Affects the Antimicrobial Activity
To investigate how the positioning of the fatty acid influence antimicrobial activity, peptides with
similar structures (number of hydrophobic residues and charge) were compared. The cyclic lipopeptides
were screened against wild-type isolates belonging to the ESKAPE group of pathogens (see Section 3).
We included E. coli in the screen as a representative of Enterobacteriaceae. Overall, there were no
differences in antimicrobial activity when comparing the MICs determined for (C10)1, (C10)4, and (C10)8.
In contrast, there were some indications that the positioning of the fatty acid had importance when
hydrophobic aromatic residues were substituted with a modified Dab residue. As shown in Table 1,
the main difference between insertion of fatty acid tails in Positions 2 and 7 was the surrounding
residues. In Position 2, the fatty acid was adjoined by two cationic residues, whereas the flexible
linker was next to the fatty acid in Position 7. Otherwise, the overall sequences of (Cn)2 and (Cn)7
were identical. For the MICs, significant differences were observed against all bacteria. Compounds
(C12)2 and (C12)7 were especially interesting: the antimicrobial activity was reduced to one-fourth
when C12 was inserted in Position 2 as compared to Position 7. Because the fatty acid position was
the only variable, it appears that attachment to some positions in the macrocycle gave rise to higher
antimicrobial activity. This observation was further confirmed by the MICs determined for (Cn)5.
When a fatty acid moiety was inserted in Position 5, it was adjoined by a single cationic residue and the
flexible linker, as when placed in Position 7. Interestingly, the MICs for all (Cn)5 peptides (n = 4, 6, 8, 10,
12, and 14) were similar to those found for the corresponding (Cn)7 peptides (n = 4, 6, 8, 10, 12, and 14),
even though the peptides had slightly different sequences. It could therefore be hypothesized that it is
favorable to introduce a fatty acid in the vicinity of a hydrophilic, flexible linker.
In a study concerning lipidated cyclic γ-AApeptides, Li et al. found that attachment of fatty
acid tails directly to the rigid macrocyclic structure only gave rise to analogues that possessed weak
antimicrobial activity [25]. The reason for this could be that the lipid tail had limited flexibility when
attached to the ring structure, thus reducing its ability to insert efficiently into the bacterial membrane.
When the lipid tail was moved away from the cyclic structure by insertion of at least two residues
between the macrocycle and the fatty acid, the antimicrobial activity was enhanced substantially.
This indicated that incorporation of flexible parts into macrocycles might possibly confer less constriction
to the movement of the lipid tail [25]. A flexible linker such as 8-amino-3,6-dioxaoctanoic acid (O2Oc)
also creates a discrete region of flexibility in an otherwise constrained macrocycle. Therefore, it was
reasonable to assume that the flexible linker modified the conformation of the region around it, and thus
facilitated the lipid tail to anchor deeply into the bacterial membrane. Furthermore, consistent with Li
et al., addition of fatty acids in more rigid positions in the S3(B) analogues, e.g., in Position 2, did not
lead to enhanced antimicrobial activity. Therefore, it is suggested that a certain degree of flexibility
around the fatty acid moiety is essential to confer antimicrobial properties.
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2.1.3. The Influence of Cationic Residues in AMPs
When C10 fatty acids were attached at Positions 1, 4, and 8 in the macrocycle, the net positive
charge was reduced as compared to that of the lead structure. For all three analogues, the activity
against E. coli and P. aeruginosa was completely lost (MIC > 64 µg/mL). Based on this observation, it is
hypothesized that reducing the number of cationic residues in the AMPs led to a decreased electrostatic
interaction between the peptide and the negatively charged bacterial lipopolysaccharide (LPS). Several
studies have investigated the influence of charge on antimicrobial activity of AMPs. Giangaspero et al.
showed that decreasing or increasing the net positive charge of AMPs either reduced or enhanced the
antimicrobial activity, respectively [26]. Likewise, Dathe et al. showed that increasing the net positive
charge from +3 to +4 or from +4 to +5 (threshold) gradually increased the antimicrobial activity [27].
It is therefore reasonable that the decrease in charge from +4 to +3 in some of our fatty acid analogues
could be an explanation for the loss of activity. However, the activity against S. aureus and A. baumannii
(8–16 µg/mL) determined for (C10)1, (C10)4, and (C10)8 was comparable to that of S3(B). Thus, E. coli
and P. aeruginosa are clearly more sensitive to alterations of the net charge of certain AMPs, possibly
because this leads to weaker electrostatic interactions with bacterial membranes.
2.1.4. The Influence of Fatty Acid Length
To investigate the effect of attaching fatty acids to a macrocycle, fatty acid tails of different lengths
were used. When the carbon chain was elongated, the hydrophobicity of the peptide was increased
gradually. Herein, the hydrophobicity is expressed as the percentage of mobile phase B at the peak
elution time on an RP-HPLC system. As expected, all lipidated analogues displayed relatively high
hydrophobicity due to the presence of a fatty acid tail.
Generally, opposing trends for antimicrobial and hemolytic activity were found when the fatty
acid length was increased. An example is shown in Figure 2.
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The antimicrobial activity against P. aeruginosa (blue curve) and hemolytic activity at 150 µM
(red curve) for the (Cn)5 peptides are illustrated as a function of increasing hydrophobicity
(via elongating the fatty acid from C4 to C14). It is generally accepted that increasing hydrophobicity
of AMPs typically leads to enhanced hemolytic properties. In the same way, some hydrophobicity
of an AMP is required for bacterial membrane permeabilization, and it usually confers improved
antimicrobial activity [28].
2.2. Antimicrobial Activity
As illustrated in Figure 2, it was clear that an optimum in fatty acid chain length existed. When the
lipid tail was shorter than this most effective length (i.e., C10 with an optimal MIC of 4 µg/mL against
P. aeruginosa; 4–16 µg/mL against other bacteria) the potency was lowered, gradually reaching MICs of
32 µg/mL or higher. In contrast, when the lipid tail was elongated beyond C10, the activity gradually
decreased to a MIC of 64 µg/mL. When comparing the MICs for all tested species, the antimicrobial activity
of the fatty acid modified analogues was lowered significantly (to MICs of 16 µg/mL or higher) when
fewer than eight or more than twelve carbon atoms were present in the lipid tail. These observations may
possibly be interpreted as a too-short fatty acid tail being unable to penetrate the bacterial membrane,
consequently causing lack of activity. In contrast, tails longer than the maximum effective length could
induce aggregation (or adsorption to test plates) and subsequently inactivation of AMPs due to strong
hydrophobic interactions between the fatty acid tails [29]. Thus, the best activity was obtained when C10
fatty acids were attached at Positions 5 or 7, i.e., to give lipopeptides (C10)5 and (C10)7.
Importantly, the present results were in agreement with the relationship between peptide
hydrophobicity and antimicrobial activity observed in a study conducted by Chen et al. [28]. In that
study, alteration in hydrophobicity was achieved via amino acid substitutions, while in the present
work hydrophobicity was varied by modification with fatty acids. Therefore, it is difficult to assess
whether the antimicrobial activity mainly is determined by the change in overall hydrophobicity
or whether the ability of the fatty acid moiety to anchor the molecule in the bacterial membrane
also contributed. No differences were seen when the antimicrobial activity of S3(B) is compared to
the activity of the equally hydrophobic analogue (C8)7. This indicates that the length of fatty acid
contributed to the peptide hydrophobicity and amphipathic structure, whereas further ability to
enhance activity through membrane anchoring appeared to be of minor importance for this class
of cyclic lipopeptides. In other studies, it has been shown that membrane binding only is slightly
increased for lipopeptides containing a single fatty acid moiety. Thus, the lipid tail’s contribution to
the overall binding enthalpy may be negligible. In contrast, when two fatty acid chains were attached
to a peptide, the lipid tails were firmly anchored in the membrane [30].
2.2.1. Hemolytic Activity
Hemolysis of red blood cells is often used as a preliminary assessment of antimicrobial peptides [31].
The lowest hemolytic activity was found for (C4)5, and it was gradually increased with increasing fatty
acid chain length. Increasing the fatty acid length from C8 to C10 led to a pronounced increase in the
hemolytic properties (Table 1). The critical length for fatty acid to confer hemolytic properties to the
lipopeptide was found to be more than eight carbon atoms. This tendency was consistent with data
obtained for the (Cn)7 peptides as well.
With regards to hydrophobicity, only the C4-, C6-, and C8-modified peptides were less hydrophobic
than the original S3(B), whereas the hydrophobicity was increased when the fatty acid length was
extended further. In addition, only the C4-, C6-, and C8-modified peptides had lower hemolytic activity
than S3(B). The peptides that were more hydrophobic than S3(B), i.e., all lipopeptides with fatty acids
longer than eight carbon atoms, were found to be highly hemolytic, with induction of 100% hemolysis
at 150 µM. When the hydrophobicity was too pronounced, the AMPs were not able to differentiate
between cells based on hydrophobic interactions. Because S3(B) naturally was relative hydrophobic
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and hemolytic with an HD50 of 69 µM (Figure 3), more hydrophobic analogues may have been able to
penetrate deeper into the hydrophobic core of human erythrocytes, thereby causing lysis of cells [28].
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Because of the different optima for antimicrobial and hemolytic activity based on peptide
hydrophobicity, choosing a peptide candidate for further studies was a compromise. Here, nontoxic peptides
were without antimicrobial activity, while the peptides showing the best antimicrobial profile were too
hemolytic. Therefore, the peptide with the best antimicrobial activity combined with an acceptably low
human toxicity was considered to meet the requirements for further analysis. As the antimicrobial activity
of all (Cn)5 and (Cn)7 peptides generally was very similar, the hemolytic activity was the determining factor.
When inspecting both antimicrobial and hemolytic activities, the C8-modified peptides were considered the
most promising analogues. Since the hemolytic activity of (C8)5 was lower than that of (C8)7, the former
was selected for further investigation.
2.2.2. (C8)5: The Most Promising Lipopeptide Analogue of S3(B)
Overall, the results indicated that the most promising S3(B) lipopeptide analogue was (C8)5.
This analogue showed antimicrobial activity corresponding to that of S3(B) against all tested
bacteria, with highest potency observed against S. aureus and P. aeruginosa with MICs of 8 µg/mL.
However, a significantly lower hemolytic activity was observed for (C8)5 (HD50 > 150 µM) as
compared to 69 µM for S3(B). As discussed above, the optimum in antimicrobial activity did not
co-occur with low hemolytic activity, making (C8)5 the best choice out of the synthesized peptides.
Furthermore, we expected (C8)5 to be relatively stable in serum, since cyclic peptides are significantly
more resistant to proteolytic breakdown than linear peptides.
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2.2.3. Hemolytic Activity: (C8)5 Versus S3(B)
Differences in hemolytic activity for (C8)5 and S3(B) were observed across the entire investigated
concentration range 2.35–150 µM. This is illustrated in Figure 3. As expected, the degree of hemolysis
was dependent on the peptide concentration; more erythrocytes were affected and lysed when
increasing amounts of peptide molecules were available. Therefore, the curves in Figure 3 represent
the typical pattern for a hemolytic profile [31]. An explanation for the less hemolytic profile for (C8)5
as compared to that of S3(B) might be the peptide hydrophobicity, even though the difference was
small. When the hydrophobicity was slightly increased, highly hemolytic peptides were obtained,
suggesting that a threshold in hydrophobicity close to that of (C8)5 existed.
2.2.4. Time-Kill Experiment of (C8)5 Against P. aeruginosa
The MIC constitutes a limited measure for antimicrobial activity. It indicates whether or not
AMPs in different concentrations are able to prevent visible growth of bacteria. However, it does
not provide information about the time course of the antimicrobial effect or about how effective the
agent is, i.e., the fraction of bacteria being killed during the period of treatment. Therefore, a time-kill
experiment of (C8)5 was performed against P. aeruginosa. Using different peptide concentrations of
1×MIC (8 µg/mL) and 5×MIC (40 µg/mL), important information about the rate and extent of bacterial
killing as a function of concentration was generated. For comparison, colistin 5 ×MIC (2.5 µg/mL) and
S3(B) 1 ×MIC (8 µg/mL) were used as reference compounds.
As illustrated in Figure 4, the data obtained for (C8)5 clearly showed that the peptide exhibited
concentration-dependent killing against P. aeruginosa. Thus, when treated for 1 h, the cell count
was reduced differently; a 4.5-log reduction was observed at 5 × MIC compared to 1 × MIC.
This corresponded to killing of >99.9% of the bacteria in the original inoculum. In contrast, when treating
with a concentration equal to the MIC, the bacterial cell count did not change over the first 5 h, indicating
a more bacteriostatic effect at this concentration. For comparison, 2.5-log and 4.5-log reductions were
found within the first hour of treatment for S3(B) and colistin, respectively. The data obtained for S3(B)
and colistin were comparable to previous data for the two compounds [18]. However, the difference
in effect between S3(B) and (C8)5 indicated that the lipopeptide derivative was less bactericidal than
the original cyclic peptide. The high-dose treatment with (C8)5 showed high initial bactericidal
activity, followed by a plateau, and finally, slow regrowth seemed to occur. This effect was unexpected.
There was a clear concentration-dependent activity of the peptide, which was expected due to the
fact that AMPs mainly act through binding to the bacterial membrane, and not through a specific
target, e.g., receptors which can be saturated because of occupation of binding sites. When the
peptide concentration is increased, more molecules are available to bind to the bacterial membrane.
Therefore, more cells can potentially be affected and killed as compared to treatment with a lower
peptide concentration.
It seemed likely that a concentration equal to the MIC of (C8)5 was able to maintain the bacterial
concentration of the original inoculum for 5 h. However, this effect was transient, and after 24 h, the cell
count was increased to the same level as the growth control (~1010 CFU/mL). This transient effect was
also seen for S3(B), but with an initial bactericidal phase. After five hours of treatment with 5 ×MIC,
the bacterial concentration was similar to the concentration obtained upon exposure to 1 ×MIC of
(C8)5. Because the antimicrobial effect is highly dependent on the number of viable cells relative to the
amount of available drug molecules, variation is commonly observed.
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Additionally, the MIC determinations were performed using different growth conditions than
during the time-kill experiment. In the latter, the bacterial suspension was shaken and aerated during
growth, thereby ensuring optimal growth conditions for the bacteria. Therefore, it is possible that the
antimicrobial concentration determined in the MIC assay differed from the concentration needed to
kill bacteria when more favorable growth conditions are provided. Colistin was the only peptide that
retained a high bactericidal activity over 24 h. No growth was observed in any of the colistin-treated
samples. When no growth of bacteria was observed, the CFU/mL was therefore set at the detection
limit of 10 CFU/mL. The remaining peptide preparations were not able to prevent growth completely
for more than one hour, as regrowth of P. aeruginosa then occurred. Applying 5 ×MIC of (C8)5 gave a
slightly increased duration; however, cells regrew to 104 after 24 h when the experiment was terminated.
Overall, the antimicrobial activity of (C8)5 was concentration-dependent, with high killing efficacy
when an appropriate concentration was used. However, it was only possibly to maintain the high
bactericidal effect (>99.9% killing) for one hour.
3. Materials and Methods
3.1. Chemistry
TentaGel® S RAM resin, TFA, piperidine, Fmoc-8-amino-3,6-dioxaoctanoic acid, and all Fmoc-protected
l-amino acids were purchased from Iris-Biotech GmbH, Marktredwitz, Germany DIEA, triisopropylsilane,
PBS, melitin, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholiniumtetrafluoroborate (DMTMM.BF4),
and 2% hydrazine in DMF and fatty acids were from Sigma-Aldrich (St. Louis, MO, USA);
HOAt (1-hydroxy-7-azabenzotriazole) and HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo
[4,5-b]pyridinium-3-oxid hexafluorophosphate, N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide), were from GL Biochem
(Shanghai, China) DMF (dimethylformamide, synthesis grade), DCM (dichloromethane, optical grade),
and ACN (acetonitrile, optical grade) were from VWR (Copenhagen, Denmark). Disposable 5 mL
polypropylene reactors fitted with PTFE filters were acquired from Thermo Scientific
(Copenhagen, Denmark).
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3.2. Peptides
Peptides were purified via preparative RP-HPLC on a preparative WatersTMXBridgeTM BEH130
C18, HPLC column (5µm; 10× 250 mm) equipped with a WatersTM Cartridge Holder PKG (10× 10 mm).
MicroflexTM (Bruker Corporation, Bremen, Germany). FlexControl software (Bruker Daltonik GmbH,
Bremen, Germany) was used to obtain the spectra, and the data were processed using flexAnalysis
(Bruker Daltonik GmbH). All reagents and solvents were used without further purification.
3.3. Microbiology and Hemolysis
Cation-adjusted Mueller-Hinton broth (MHB-II) media (BD BBLTM Beef extract powder,
BD BactoTMCasamino acids, and DIFCO soluble starch was from Becton, Dickinson and Company©,
Franklin Lakes, NJ, USA). MHB media supplemented with 0.2% BSA was from Sigma Aldrich
(St. Louis, MO, USA) and 0.01% acetic acid from VWR®. The 96 well plate cell-culture cluster,
round-bottom, polypropylene plates, and V-shaped 96 well polypropylene plates were purchased
from Corning® Inc., Costar®, Corning, NY, USA. Microseal® film was obtained from Bio-Rad
Laboratories, Inc., Hercules, CA, USA. A VersaMaxTM Tunable Microplate Reader (Molecular
Devices LLC, Sunnyvale, CA, USA) was used and the data were evaluated on a Softmax® Pro
(Molecular Devices LLC). [32]
3.4. Peptide Synthesis
Peptides were synthesized according to standard Fmoc-based SPPS procedures, which were
performed on a TentaGel S RAM resin (loading 0.24 mmol/g). Overall, the synthesis consisted of cycles
of Fmoc deprotection, washing, amino acid coupling, and washing. Afterwards, macrocyclization,
fatty acid acylation, and finally cleavage from the resin were performed [18].
3.5. Fmoc Deprotection
The Fmoc-protected RAM linker was deprotected using 20% piperidine in DMF. A volume of
3 mL was transferred into the syringe, which was allowed to stand for 4 min. Afterwards, the syringe
was drained and washed with DMF (2×). The procedure was repeated twice followed by a full wash
of the resin: DMF (4×), DCM (3×), and DMF (4×).
3.6. Initiation and Preparation of Syringes
The resin (300 mg) was weighed directly into a disposable 5 mL syringe fitted with a PTFE filter.
The piston was inserted into the syringe and pushed just above the resin. DMF was drawn into the
syringe and it was left to swell for at least 2 h. After swelling, the syringe was drained, the piston
was removed, and the syringe was placed in a suction plate connected to a 2 L Büchner flask and a
vacuum pump.
3.7. Coupling of Amino Acids
HOAt and HATU were weighed off separately and were dissolved in DMF as stock solutions
(0.4 M). Four molar equivalents of amino acids and coupling reagents and eight equivalents of DIEA
were used. The amino acids were weighed directly into appropriate tubes, and were dissolved in the
HOAt stock solution. The amino acid solutions were kept in the freezer until use. Before coupling of an
amino acid, HATU was transferred into the tube containing amino acid followed by addition of DIEA.
The tube was gently shaken (color change to yellow) and was drawn up into the syringe. The syringe
was wrapped in alufoil and placed on a shaker for 1.5 h at room temperature. Between double
couplings, the resin was washed with DMF (2×). Between coupling of different amino acids, the resin
was washed with DMF (6×), treated with 20% piperidine in DMF and washed with DMF (10×).
The elongation with amino acids was continued until the final linear peptide was assembled.
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3.8. Peptide Macrocyclization
To allow cyclization, the resin was treated with 1.5% TFA in DCM for 5 min to remove the
Dmb group. This was repeated eight times in total, or more if necessary; through the treatments,
the solution had to change color into red, indicating that the Dmb removal was driven to completion.
The resin was washed with DMF (5×), DCM (5×), and EtOH (5×) following by lyophilization overnight.
The lyophilized resin was allowed to swell in DMF for at least 2 h before initiation of the cyclization.
DMTMM (3 equivalents) was weighed directly into an Eppendorf tube and was dissolved in a small
amount of DMF. Six equivalents of DIEA was added to the solution, which then was drawn into
the syringe. The peptide was left for cyclization overnight on a shaker. Afterwards, the resin was
washed with DMF (5×). The procedure was repeated with 3 equivalents of DIEA. After completion
of the cyclization, the resin was washed with DMF (3×), DCM (3×), and EtOH (5×), followed by
lyophilization overnight.
3.9. Fatty Acid Acylation
To allow acylation, the ivDde group was removed. The lyophilized resin was allowed to swell in
DMF for 30 min. Deprotection was accomplished via three treatments with a freshly prepared solution
of 2% hydrazine in DMF. To each syringe, 3 mL (equal to 10 mL per g resin) of the solution was drawn
up, and then the syringe was placed on a shaker for 15 min. The resin was washed with DMF (2×),
and the procedure was repeated twice. After the third treatment, the resin was washed with DMF
(3×) and DCM (3×), and it was allowed to dry completely. Fatty acids were weighed and dissolved
in HOAt stock solution. The procedure for coupling of fatty acids was identical to the coupling of
amino acids described above. Double couplings were performed, in which one of the couplings was
carried out overnight. Finally, the resin was washed with DMF (3×), DCM (3×), and EtOH (5×) and
lyophilized for at least 1.5 h.
3.10. Peptide Cleavage
The peptide was cleaved from the resin using a freshly prepared cleavage cocktail consisting of
TFA/H2O/TIS (95:2.5:2.5 (v/v)) or TFA/H2O/DTT/TIS (88:5:5:2). Three milliliters of the cocktail was
drawn into the syringe, the syringe was capped with a pressure cap, and the syringe was left on a
shaker for two hours. Afterwards, the cleavage solution was pushed into a 5 mL cryotube. The piston
was removed from the syringe and the resin was washed with cleavage cocktail, and then the eluate
was collected in the cryotube. The collected cleavage solution was evaporated using a gentle stream
of nitrogen until approximately 300 µL was left. An amount of 4 mL cold diethyl ether was added
to the remaining solution, resulting in precipitation of the peptide. The tube was shaken gently and
centrifuged (2000 rpm) for 6 min. The supernatant was removed and the procedure by adding diethyl
ether was repeated twice using 2000 rpm and 4000 rpm, respectively. The cryotube was left to stand
in the fume hood, allowing evaporation of the residual ether. After obtaining a dry crude, this was
dissolved in a minimum freeze-drying solution (10% ACN and 0.1% TFA in water) and was left in the
freezer (−80 ◦C) until it was completely frozen. The peptide (TFA salt) was lyophilized overnight to
obtain a fluffy white solid.
3.11. Minimum Inhibitory Concentration Determination
The MIC experiments were performed according to a protocol adapted from Wiegand et al. [24],
with minor modifications. The MICs were determined in triplicate. The peptides were dissolved in
Milli-Q water to produce 10 mg/mL stock solutions in small glass containers. The bacterial isolates
to be tested were streaked onto agar plates to obtain single colonies, and the plates were incubated
at 37 ◦C for 18–24 h. The strains tested were S. aureus ATCC 29213, P. aeruginosa ATCC 27853, E. coli
ATCC 25922, A. baumannii ATCC 19606, and K. pneumonia ATCC 13883. Test compounds were prepared
in 2-fold dilutions in 50 µL volumes in polypropylene microtiter plates. Bacterial cultures grown to
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OD600 = 0.1–0.4 were diluted to a desired OD600 of 0.001–0.002 corresponding to 1 × 106 CFU/mL.
Next, 50 µL bacterial suspension was added to the microtiter plates, giving a final bacterial inoculum
of 5 × 105 CFU/mL per well. The plates were incubated at 37 ◦C for 18–24 h. To verify the CFU, 10 µL
from the positive control was transferred to 990 µL 0.9% NaCl. From this, a 10-fold dilution series was
made; 100 µL of the diluted bacteria was plated onto three LB plates, and these were incubated at 37 ◦C
for 18–24 h. A cell count of 3–7 × 105 CFU was considered acceptable. The MIC values were visually
evaluated, and the MIC was set to the lowest concentration with visible growth based on triplicate
measurements. Colistin and vancomycin were used as control antibiotics.
3.12. Hemolysis
The hemolysis experiments were performed according to the protocol described in Reference [31].
The peptides were tested at concentrations from 2.35–150 µM, using melittin as positive control and PBS
as negative control. One premade tablet of PBS was dissolved in 200 mL Milli-Q water. The solution
was kept in the refrigerator for a maximum of two days. The day before the test, the positive control
wells of the 96 well polypropylene plates were precoated with 150 µL of melittin 5 µM solution in PBS.
The solution was prepared in Protein LoBind Eppendorf tubes. The day of the test, the solution was
discarded and the wells were washed three times with 150 µL PBS. A melittin 2.50 µM solution in
PBS was prepared in Protein LoBind Eppendorf tubes—500 µL for every plate to be used. The mass
of the peptide needed to reach a final concentration of 300 µM (to start testing down from 150 µM)
was calculated, since a volume of 500 µL was desirable. Because the peptides were obtained as TFA
salts during cleavage, this had to be taken into consideration in the calculations. The peptides were
dissolved in PBS and tested in triplicate.
In a 96 well polypropylene plate, 150 µL of peptide solution was transferred to three wells in
Row A. Therefore, each plate could accommodate up to four peptides. A 2-fold serial dilution of the
peptides was obtained by transferring 75 µL of the solutions from Row A to the corresponding wells in
Row B, mixing a couple of times. From Row B, 75 µL was transferred to Row C and so on until Row
G, where 75 µL was discarded after mixing. Volumes of 75 µL melittin (2.50 µM) was transferred to
the positive control wells in H1–H6. Preparation of the RBC suspension: 1 mL of whole blood was
transferred to a cryotube with 3 mL of PBS, and then it was gently mixed and centrifuged for 8 min at
3000 rpm. The supernatant was discarded, and the process was repeated twice; with 4 mL at 3000 rpm
and 4 mL at 4000 rpm, respectively. From the final RBC pellet, 40 µL was transferred to 8 mL of PBS
(multiplied by the number of test plates needed). This corresponded to a 0.5% v/v RBC suspension.
The suspension was gently mixed and transferred into a CAPPOrigami reservoir. Using a multichannel
pipette, 75 µL of the suspension was transferred into each well and mixed in the direction of increasing
concentration. The control wells were mixed separately. The plates were covered with BioradMicroseal
foil and incubated at 37 ◦C for 1 h. The plates (maximum two) were centrifuged for 10 min at 4000 rpm,
followed by transferring of supernatant (60 µL) from each well into the corresponding wells in a clear
ELISA plate. The absorbance (A) of each well was measured at λ = 414 nm using the software program
Softmax(R) Pro.
3.13. Time-Kill Kinetics
Time-kill experiments were performed on balanced exponentially growing cultures of P. aeruginosa
ATCC 27853. We used balanced cultures as described in Oddo et al. [33]. Briefly, overnight cultures
were prepared in MHB-II broth at 37 ◦C with shaking. Overnight cultures were back-diluted and grown
exponentially for no less than 8–10 generations before experimentation. When experiments were done,
exponentially growing cultures were back-diluted to an OD600 = 0.0005 approximately 5 × 105 CFU,
into fresh MHB-II heated to 37 ◦C. Samples (250 µL) were taken at time points 0, 1, 3, 5, and 24 h.
Samples were spun down at 8000× g for 5 min and washed in 1 mL of NaCl 0.9% before being spun
down again and re-suspended in 250 µL NaCl 0.9%. From this, 10-fold dilution series were prepared
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and 10 µL samples were spot-plated in triplicate onto LB-agar. From the undiluted sample, 100 µL
samples were also plated, i.e., giving a detection limit of 10 CFU/mL.
4. Conclusions
A total of 18 fatty acid analogues of the flexible cyclic antimicrobial peptide S3(B) were synthesized
in the present study. The peptides were cyclized head-to-tail, which generally makes peptides
constricted and rigid molecules. However, by introducing a flexible residue (i.e., O2Oc) into the
structure, it was possible to create a localized flexible region. Colistin and other cyclic lipopeptides
naturally contain fatty acid tails that are essential for their antimicrobial activity. Therefore, the aim of
this work was to investigate how the antimicrobial and hemolytic activity was affected by introduction
of fatty acid chains of different lengths and in different positions in the macrocyclic structure of S3(B).
Two main types of analogues were synthesized: (i) highly hydrophobic peptides in which a fatty
acid moiety was attached to an existing Dab residue: (Cn)1,(Cn)4, and (Cn)8, and (ii) peptides in which a
Dab carrying a fatty acid chain was incorporated instead of an aromatic residue: (Cn)2,(Cn)5, and(Cn)7.
Only modification with a C10 fatty acid was examined for Positions 1, 4, and 8, whereas introduction of
fatty acid chains of varying lengths (C4 to C14) was examined for Positions 2, 5, and 7. Generally it
was found that the positioning of the fatty acid seemed to be important for the antimicrobial activity.
When the fatty acid was inserted in Position 5 or 7, the activity against several bacterial species were
enhanced significantly as compared to that of other subtypes. Overall, the best antimicrobial activity
was obtained when C8–C12 fatty acids were inserted at Positions 5 and 7. For shorter and longer lipid
tails, the antimicrobial activity was lowered considerably or even completely lost. However, it was not
possible to enhance the antimicrobial activity as compared to that of the original nonacylated S3(B).
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Abbreviations
ACN Acetonitrile
Bip l-biphenylalanine
BSA Bovine Serum Albumin
CFU Colony-forming unit
Dab l-2,4-diaminobutyric acid
DCM Dichloromethane
DIEA Disopropylethylamine
Dmb 2,4-Dimethoxybenzyl
DMF Dimethylformamide
DMTMM.BF4 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium tetrafluoroborate
DTT Dithiothreitol
EUCAST European Committee on Antimicrobial Susceptibility Testing
Fmoc 9-fluorenylmethoxycarbonyl
HA Hemolytic activity
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluoro-phosphate,
N-[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethan-aminium hexa-fluorophosphate
N-oxide)
HOAt 1-Hydroxy-7-azabenzotriazole
IvDde 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl
LPS Lipopolysaccharide
MALDI-TOF MS Matrix-assisted linear desorption Time-Of-Flight Mass Spectrometry
MHB Mueller-Hinton broth
MIC Minimum Inhibitory Concentration
Nal 3-(2-Naphthyl)-l-alanine
O2Oc 8-amino-3,6-dioxaoctanoic acid
PBS Phosphate-buffered saline
RAM Rink amide
RBC Red blood cell
RP-HPLC Reverse Phase Analytical High Performance Liquid Chromatography
rpm Rotations per minute
SPPS Solid-Phase Peptide Synthesis
TFA Trifluoroacetic acid
TIS Triisopropylsilane
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